Ivan Marchena

BD-02 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE

S. Faraone, A. Perl, Z. Lai, 2018, Big Data Analyses.

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

S. Faraone, A. Perl, Z. Lai, 2018, The Lancet.